Serveur d'exploration COVID et hydrochloroquine - Exploration (Accueil)

Index « Keywords » - entrée « Lopinavir (adverse effects) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Lopinavir (administration & dosage) < Lopinavir (adverse effects) < Lopinavir (blood)  Facettes :

List of bibliographic references indexed by Lopinavir (adverse effects)

Number of relevant bibliographic references: 28.
[0-20] [0 - 20][0 - 28][20-27][20-40]
Ident.Authors (with country if any)Title
000020 (2021) Fabio Cruciani [Italie] ; Laura Amato [Italie] ; Franco De Crescenzo ; Zuzana Mitrova [Italie] ; Rosella Saulle [Italie] ; Simona Vecchi [Italie] ; Marina Davoli [Italie][The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.]
000091 (2021) Fatemeh Sadat Hosseini [Iran] ; Alireza Malektojari [Iran] ; Sara Ghazizadeh [Iran] ; Mehdi Hassaniazad [Iran] ; Parivash Davoodian [Iran] ; Habib Dadvand [Iran] ; Amin Reza Nikpoor [Iran] ; Sara Nikoofal-Sahlabadi [Iran] ; Sara Kahoori [Iran] ; Mojtaba Sepandi [Iran] ; Soheil Hassanipour [Iran] ; Mohammad Fathalipour [Iran]The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
000114 (2021) Viveksandeep Thoguluva Chandrasekar [États-Unis] ; Bhanuprasad Venkatesalu [États-Unis] ; Harsh K. Patel [États-Unis] ; Marco Spadaccini [Italie] ; Jacob Manteuffel [États-Unis] ; Mayur Ramesh [États-Unis]Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection.
000156 (2021) Etienne Meriglier [France] ; Claire Rivoisy [France] ; Mojgan Hessamfar [France] ; Noelle Bernard [France] ; Ines Aureau [France] ; Joelle Lapoirie [France] ; Anne Contis [France] ; Frédéric Sacher [France] ; Benjamin Sacristan [France] ; Marin Lahouati [France] ; Stéphane Pedeboscq [France] ; Marie-Anne Vandenhende [France] ; Stéphane Bouchet [France] ; Fabrice Bonnet [France]Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
000234 (2021) Carlos Diaz-Arocutipa [Pérou] ; Ana Bra Ez-Condorena [Pérou] ; Adrian V. Hernandez [Pérou, États-Unis]QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
000295 (2021) Zheng Zequn [République populaire de Chine] ; Wu Yujia [République populaire de Chine] ; Qian Dingding [République populaire de Chine] ; Lian Jiangfang [République populaire de Chine]Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
000297 (2021) Havva Kocayi It [Turquie] ; Kezban Özmen Süner [Turquie] ; Yakup Tomak [Turquie] ; Gürkan Demir [Turquie] ; Selçuk Yaylac [Turquie] ; Hamad Dheir [Turquie] ; Ertu Rul Güçlü [Turquie] ; Ali Fuat Erdem [Turquie]Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
000353 (2021) Ji-Won Kim [Corée du Sud] ; Eun Jin Kim [Corée du Sud] ; Hyun Hee Kwon [Corée du Sud] ; Chi Young Jung [Corée du Sud] ; Kyung Chan Kim [Corée du Sud] ; Jung-Yoon Choe [Corée du Sud] ; Hyo-Lim Hong [Corée du Sud]Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
000506 (2021) Barbara Burgos-Blasco [Espagne] ; Noemi Güemes-Villahoz [Espagne] ; Beatriz Vidal-Villegas [Espagne] ; Juan Donate-Lopez [Espagne] ; Julian Garcia-Feijoo [Espagne]Evaluation of retinotoxicity of COVID-19 treatment: Hydroxychloroquine and lopinavir/ritonavir.
000612 (2021) Jennifer Carron [Irlande (pays)] ; Zain Sharif [Irlande (pays)] ; Hafiz Hussein [Irlande (pays)] ; Mark Kennedy [Irlande (pays)] ; Brendan Mcadam [Irlande (pays)] ; Richard Sheahan [Irlande (pays)]Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.
000690 (2021) Carlotta Sciaccaluga [Oman] ; Matteo Cameli [Italie] ; Daniele Menci [Italie] ; Giulia Elena Mandoli [Italie] ; Nicol Sisti [Italie] ; Paolo Cameli [Italie] ; Federico Franchi [Italie] ; Sergio Mondillo [Italie] ; Serafina Valente [Italie]COVID-19 and the burning issue of drug interaction: never forget the ECG.
000805 (2020) Naeem A. Alshoaibi [Arabie saoudite] ; Khadijah Maghrabi [Arabie saoudite] ; Haitham Alanazi [Arabie saoudite] ; Mousa Al Harbi [Arabie saoudite] ; Saleh Alghamdi [Arabie saoudite]Saudi Heart Rhythm Society Task Force on Management of Potential Arrhythmogenicity Associated with Pharmacotherapy for COVID-19.
000807 (2020) Melanie Bilbul [États-Unis] ; Patricia Paparone [États-Unis] ; Anna M. Kim [États-Unis] ; Shruti Mutalik [États-Unis] ; Carrie L. Ernst [États-Unis]Psychopharmacology of COVID-19.
000867 (2020) Saleh A. Alqahtani [Arabie saoudite, États-Unis] ; Abdulrahman A. Aljumah [Arabie saoudite] ; Almoutaz Hashim [Arabie saoudite] ; Thamer H. Alenazi [Arabie saoudite] ; Mohammed Aljawad ; Waleed K. Al Hamoudi [Arabie saoudite] ; Mohammed Y. Alghamdi [Arabie saoudite]Principles of Care for Patients with Liver Disease During the Coronavirus Disease 2019 (COVID-19) Pandemic: Position Statement of the Saudi Association for the Study of Liver Disease and Transplantation.
000885 (2020) Alexandre Gérard [France] ; Serena Romani [France] ; Audrey Fresse [France] ; Delphine Viard [France] ; Nadège Parassol [France] ; Aurélie Granvuillemin [France] ; Laurent Chouchana [France] ; Fanny Rocher [France] ; Milou-Daniel Drici [France]"Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.
000920 (2020) Áurea Redondo-Sendino [Espagne] ; Isabel Cristina González Sánchez [Espagne] ; Beatriz De Victoria Fernández [Espagne][Skin manifestations associated with the new coronavirus SARS-CoV-2 disease].
000A13 (2020) John R. Giudicessi [États-Unis] ; Peter A. Noseworthy [États-Unis] ; Paul A. Friedman [États-Unis] ; Michael J. Ackerman [États-Unis]Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).
000A80 (2020) Marilù Bartiromo [Italie] ; Beatrice Borchi [Italie] ; Annarita Botta [Italie] ; Alfredo Bagalà [Italie] ; Gianmarco Lugli [Italie] ; Marta Tilli [Italie] ; Annalisa Cavallo [Italie] ; Brunilda Xhaferi [Italie] ; Roberta Cutruzzulà [Italie] ; Augusto Vaglio [Italie] ; Silvia Bresci [Italie] ; Aida Larti [Italie] ; Alessandro Bartoloni [Italie] ; Calogero Cirami [Italie]Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19).
000B22 (2020) Parham Habibzadeh [Iran] ; Mohsen Moghadami [Iran] ; Kamran Bagheri Lankarani [Iran]The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.
000C15 (2020) Alem Zekarias [Suède] ; Sarah Watson [Suède] ; Sara Hedfors Vidlin [Suède] ; Birgitta Grundmark [Suède]Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
000C40 (2020) Katarina Barali [Serbie] ; Dragica Jorgovanovi [Serbie] ; Katarina Živan Evi [Serbie] ; Evica Antonijevi Miljakovi [Serbie] ; Biljana Antonijevi [Serbie] ; Aleksandra Buha Djordjevic [Serbie] ; Marijana Ur I [Serbie] ; Danijela Uki Osi [Serbie]Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Lopinavir (adverse effects)" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Lopinavir (adverse effects)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Lopinavir (adverse effects)
}}

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021